Biomed Partnership Alameda Ventures The Tel Aviv-based trading company announced that it had signed a cooperation agreement with the commercialization company of Clalit Health Services, Moore Application. The collaboration will allow Almeda, which invests in digital health and medical equipment, to use information gathered at Clalit on the way to developing its products, consult with its experts and examine the products as pilots and clinical trials at Clalit. Clalit Health Services is considered a large and innovative health fund in the field of digital health, even in an international comparison, and this collaboration can yield significant value to Almeda’s portfolio companies.
The Alameda Partnership was established by Dr. Irit Yaniv, Amir Blatt and Tzachi Sultan. It raised NIS 70 million in October 2020, and it was also worth it at the time of the fundraising. Today it is traded at a value of NIS 64 million. This is after the partnership raised NIS 27 million in October. More.
Upon entering the stock market, Almeda had two investments in closure processes, Bioprotect (6.2%), a long-established company that developed a medical device designed to maintain prostate tissue safety when performing prostate cancer treatments, and TaylorMed (4.2%), a digital healthcare company that allows patients in the US In exhausting the sources of funding for their medical care.
Since entering the stock market, Almeda has made six new investments, in Norami companies (8%) – Tissue Healing Sticker after surgery, Lumen (convertible loan) – Coaching application for proper nutrition, and Reality (5.6%) – Infertility treatment, Ogmedix (2.5%) – Augmented Reality for Surgeons, Billion Life (Convertible Loan) – Digital Disease Management System for Patients and Flex Dex (8.9%) – Laparoscopy System with Robotic Elements. In total, the company invested $ 16.1 million in portfolio companies as of the end of the second half of the year.
The portfolio companies have undergone several developments since the recruitment. Last June, Taylormed raised another $ 20 million. About a month ago, Verility received FDA and CE approval to market its product in the US and Europe respectively.
Pini Ben-Elazar, CEO of Moore Implementation, Clalit Health Services, said following the signing of the agreement: “In the Israeli ecosystem, there are over 1,500 companies in the field. And in access to means and data, on the other hand. The cooperation between the R&D partnership, managed by a professional body with international relations, and an applied body, will create fertile ground for breakthroughs. “
Dr. Irit Yaniv, CEO of Alameda Ventures, said that “we anticipate that such collaboration will enable Almeda Partnership to create added value for existing portfolio companies. It intends to continue investing in additional companies operating in promising investment areas from Moore Implementation’s portfolio.”